Supplementary protection of intellectual property rights for medicines

Authors

  • A.O. Kodynets Taras Shevchenko National University of Kyiv, Volodymyrska str., 60, Kyiv, 01033, Ukraine https://orcid.org/0000-0002-0954-1474
  • O.F. Doroshenko Intellectual Property Scientific Research Institute of National Academy of Legal Sciences of Ukraine, K. Malevycha str., 11, Kyiv, 03150, Ukraine https://orcid.org/0000-0002-2542-2328
  • I.P. Volynets Intellectual Property Scientific Research Institute of National Academy of Legal Sciences of Ukraine, K. Malevycha str., 11, Kyiv, 03150, Ukraine https://orcid.org/0000-0002-2029-2165
  • G.K. Dorozhko Intellectual Property Scientific Research Institute of National Academy of Legal Sciences of Ukraine, Ukraine https://orcid.org/0000-0001-6506-3203
  • V.O. Petrenko Ukrainian State University of Science and Technologies, Institute of Industrial and Business Technologies, Haharin av., 4, Dnipro, 49005, Ukraine
  • V.V. Belitsky Dnipro State Medical University, Volodymyra Vernadskoho str., 9, Dnipro, Ukraine https://orcid.org/0000-0002-2841-7372

DOI:

https://doi.org/10.26641/2307-0404.2023.3.289223

Keywords:

medicines, intellectual property, supplementary protection certificate, legal protection, patent

Abstract

The article discusses the issue of extending the legal protection of intellectual property rights for medicines. The research aims to provide a comprehensive overview of the problems related to the implementation of Supplementary Protection Certificates (SPCs) in national legislation and possible solutions. The study also seeks to draw conclusions and make proposals for improving the regulatory framework for the SPCs of medicines. The work utilizes general scientific and specialized methods of scientific cognition, including dialectical, formal-logical, systemic-structural, comparative legal, as well as modeling, analysis, and synthesis methods, which collectively contributed to the organization, planning, and conduct of the research. The study is based on scientific publications from databases and search systems (PubMed, JAMA, Scopus, Springer, BMC, Oxford Academic), international and national regulatory acts, statistical studies by international organizations (Precedence Research), patents for inventions related to medicines, recommendations by national government bodies, as well as prescriptions and guidelines from international and national experts. Considering the analysis of statistical data on the development and implementation of medicines, it has been determined that original biological medicines are a major factor in the rising prices of treating conditions such as diabetes, oncological diseases, and others. Examples of patents for medicines owned by global pharmaceutical companies (Gilead, Bayer Intellectual Property Gmbh, etc.) that have ensured their commercial success and competitive advantages are examined. It has been established that patent protection provides the right holder with the opportunity to maintain a monopoly in the market, thereby compensating for the time spent on the development and research of original medicinal products. Legislative approaches to regulating relationships concerning the supplementary protection of inventions related to medicines in the form of SPCs in Ukraine and the EU are identified. The exclusivity periods for regulatory data protection for medicines in the EU are outlined. Based on the conducted research, it is concluded that the application of the SPC mechanism is a tool to achieve a balance between the protection of intellectual property rights and access to original medicines. Timely entry of generics and biosimilars to the market contributes to reducing market prices but negatively impacts the profitability of manufacturers of original medicines. Attention is drawn to problematic aspects of the legislative implementation of the SPC mechanism in Ukraine, which leads to incorrect interpretation and implementation of relevant provisions and necessitates updating. In light of the aforementioned, there is an urgent need in Ukraine to implement, update, and improve the legislative mechanism for regulating SPCs.

References

Wouters OJ, McKee M, Luyten J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA. 2020 Mar 3;323(9):844-53. doi: https://doi.org/10.1001/jama.2020.1166

[On protection of rights to inventions and utility models. Law of Ukraine dated 1993 Dec 15, No. 3687-XII: as of 2023 Apr 15]. [Internet]. 2023 [cited 2023 May 14]. Ukrainian. Available from: https://zakon.rada.gov.ua/laws/show/3687-12#Text

Androshchuk H. [New opportunities for European generic companies]. [Internet]. Yurydychna Hazeta online. 2019;27(681) [cited 2023 May 14]. Ukrainian. Available from: https://yurgazeta.com/publications/practice/zahist-intelektualnoyi-vlasnosti-avtorske-pravo/novi-mozhlivosti-evropeyskih-generichnih-kompaniy.html

Rabotiahova LI, Androshchuk HO. [Extending the term of validity of a patent for an invention: the inter-national legal aspect of regulation]. Pytannia intelektualnoi vlasnosti: zbirnyk naukovykh prats. 2018;15:89-108. Ukrainian.

Kodynets A, Doroshenko O, Volynets I, Dorozhko G, Petrenko V, Belitsky V. [Protection from unfair competition on the pharmaceutical market in the conditions of the COVID-19 pandemic]. Medicni Perspektivi. 2022;27(4):231-8. Ukrainian. doi: https://doi.org/10.26641/2307-0404.2022.4.271235

Hu Y, Eynikel D, Boulet P, Krikorian G. Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzumab and imatinib. Journal of pharmaceutical policy and practice. 2020;13:1. doi: https://doi.org/10.1186/s40545-019-0198-6

Vidal-Quadras M. Analysis of EU Regulation 2019/933 on the SPC Manufacturing Waiver Excep-tion. IIC - International Review of Intellectual Property and Competition Law. 2019;50(8):971-1005. doi: https://doi.org/10.1007/s40319-019-00860-7

Seuba X. The export and stockpiling waivers: new exceptions for supplementary protection certifi¬cates. Journal of Intellectual Property Law & Practice. 2019;14(11):876-86. doi: https://doi.org/10.1093/jiplp/jpz108

Lamping M, Henrique D, Batista P, Correa JI, Hilty RM, Kim D, et al. Revisiting the Framework for Compulsory Licensing of Patents in the European Union – Reflections on the European Commission’s Initiative. GRUR International. 2023;72(5):471-82. doi: https://doi.org/10.1093/grurint/ikad029

Kunst M, Kaufmann U. Authorized Generics and Biosimilars as Part of Drug Life Cycle Management. GRUR International. 2020;69(11):1105-12. doi: https://doi.org/10.1093/grurint/ikaa116

Whitehead B, Jackson S, Kempner R. Managing generic competition and patent strategies in the pharma-ceutical industry. Journal of Intellectual Property Law & Practice. 2008;3(4):226-35. doi: https://doi.org/10.1093/jiplp/jpn013

Biologics Market Size to Worth Around US$ 719.84 Bn by 2030. GlobeNewswire News Room [Internet]. 2022 Apr 20 [cited 2023 May 14]. Available from: https://www.globenewswire.com/en/news-release/2022/04/20/2425668/0/en/Biologics-Market-Size-to-Worth-Around-US-719-84-Bn-by-2030.html

Sciberras J, Zammit R, Bonanno PV. The European framework for intellectual property rights for biological medicines. Generics and Biosimilars Initiative Journal. 2021;10(4):172-83. doi: https://doi.org/10.5639/gabij.2021.1004.022

Niggins-Dunn N. The top 15 blockbuster patent expirations coming this decade. Fierce Pharma [Internet]. 2021 Jul 12 [cited 2023 May 14]. Available from: https://www.fiercepharma.com/special-report/top-15-blockbuster-patent-expirations-coming-decade

Several blockbuster patents to expire in 2023. BioStock [Internet]. 2022 Dec 16 [cited 2023 May 14]. Available from: https://www.biostock.se/en/2022/12/several-blockbuster-patents-to-expire-in-2023/

Pope C. What is the cost of Sovaldi? Why is it so expensive? [Internet]. 2023 Apr 13 [cited 2023 May 14]. Available from: https://www.drugs.com/medical-answers/cost-sovaldi-expensive-3538358/#:~:text=Sovaldi%20is%20expensive.&text=This%20means%20a%2012-week,with%20other%20treatments,%20never%20alone

First-Ever US. Patent Challenges Dispute Gi¬lead’s Monopoly on Hepatitis C Drugs that Blocks Mil¬lions from Treatment. I-MAK [Internet]. 2017 Oct 25 [cited 2023 May 14]. Available from: https://www.i-mak.org/2017/10/25/first-ever-us-patent-challenges-gilead-hepatitis-c/

[Composition (options) and method (options) of treatment of viral hepatitis C. Рat. Ukraine No. a201405757. 2017 Apr 25]; 2017. Ukrainian.

Benke K, inventor; Bayer Intellectual Property GmbH, assignee. B Solid, orally administrable pharma-ceutical composition. Рatent US No. 9.415,053 B2. 2016 Aug 16. [Internet]. [cited 2023 May 14]. Available from: https://patentimages.storage.googleapis.com/84/62/13/63f0bf483d00bb/US9415053.pdf

Misselwitz F, Kubitza D, Son-Mi Park, Wehling K, inventors; Bayer Intellectual Property GmbH, assignee. Prevention and treatment of thromboembolic disorders. Рatent US No. 9,539,218 B2. 2017 Jan 10. [Internet]. [cited 2023 May 14]. Available from: URL: https://patentimages.storage.googleapis.com/d8/a7/13/45e4c6d6fffa52/US9539218.pdf

[Substituted oxazolidinones and their use to prevent blood coagulation. Pat. Ukraine No. 2002076161. 2005 Jul 15]. Ukrainian.

Alkousaa R, Macfie N. Bayer wins EU patent extension for best-selling Xarelto drug. Reuters [Internet]. 2021 Oct 29 [cited 2023 May 14]. Available from: https://www.reuters.com/business/healthcare-pharmaceuticals/bayer-wins-eu-patent-extension-best-selling-xarelto-drug-2021-10-29/

Thompson MJ, Bader MA, Gassmann O. Patent Management: Protecting Intellectual Property and Innovation. Springer International Publishing 1. Auflage. Cham: Springer; 2021. 264 р.

Generic Drugs Market Size, Trends, Growth, Report 2022 to 2030. Precedence Research - Market Research Reports & Consulting Firm [Internet]. [cited 2023 May 14]. Availablefrom: https://www.precedenceresearch.com/generic-drugs-market

Kapitsa Yu. [Certificate of additional protection of EU medicinal products and extension of the validity period of the patent for an invention in Ukraine]. Theory and practice of intellectual property. 2016;5:69-57. Ukrainian.

Regulation (EC) No. 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (Codified version). EUR-Lex [Internet]. [cited 2023 May 14]. Available from: https://eur-lex.eu-ropa.eu/legal-content/EN/TXT/?uri=-CELEX%3A32009R0469

Regulation (EU) 2019/933 of the European Parliament and of the Council of 20 May 2019 amending Regulation (EC) No. 469/2009 concerning the supple-mentary protection certificate for medicinal products. EUR-Lex [Internet]. [cited 2023 May 14]. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32019R0933

Whittaker S, Johnson R, Walker A. Pharma-ceutical Patent Term Extension: An Overview. Pharma & Biotech Consulting | R&D & Business Support [Internet]. [cited 2023 May 14]. Available from: https://www.alacrita.com/whitepapers/pharmaceutical-patent-term-extension-an-overview#:~:text=The%20maximum%20term%20extension%20is,expiration%20(with%20term%20extension

Regulation (EC) No. 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No. 726/2004. EUR-Lex [Internet]. [cited 2023 May 14]. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32006R1901

Frequently Asked Questions: Patents. WIPO - World Intellectual Property Organization [Internet]. [cited 2023 May 14]. Available from: https://www.wipo.int/patents/en/faq_patents.html

Regulation (EC) 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and ve-terinary use and establishing a European Medicines Agency. EUR-Lex [Internet]. [cited 2023 May 14]. Available from: https://eur-lex.europa.eu/legal-content/-EN/TXT/?uri=CELEX%3A32004R0726

Regulation (EU) 2019/5 of the European Parliament and of the Council of 11 December 2018 amending Regulation (EC) No. 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, Regulation (EC) No. 1901/2006 on medicinal products for paediatric use and Directive 2001/83/EC on the Community code relating to medicinal products for human use. EUR-Lex [Internet]. [cited 2023 May 14]. Available from: https://eurlex.europa.eu/eli/reg/2019/5/oj

Doyle-Rossi M, Dirkzwager R, Beley L. EU Pharma Legislation Review Series: Unitary Supplementary Protection Certificates and Recast. Inside EU Life Sciences [Internet]. 2023 May 05 [cited 2023 May 14]. Available from: https://www.insideeulifesciences.com/2023/05/05/eu-pharma-legislation-review-series-unitary-supplementary-protection-certificates-and-recast/

Unitary Patent to Enter Into Operation on 1 June 2023: Successful Completion of the Necessary Ratification Procedures. IP Helpdesk [Internet]. 2023 Feb 20 [cited 2023 May 14]. Available from: https://intellectual-property-helpdesk.ec.europa.eu/news-events/news/unitary-patent-enter-operation-1-june-2023-successful-completion-necessary-ratification-procedures-2023-02-20_en

[Association Agreement between Ukraine, on the one hand, and the European Union, the European Atomic Energy Community and their member states, on the other hand. Agreement Ukraine dated 2014 Jun 27: as of 2022 Oct 25. Ukrainian. Available from: https://zakon.rada.gov.ua/laws/show/984_011#Text

Kashyntseva O. [Search for a legal compromise in the implementation of certificates of additional protection of inventions]. Theory and practice of intellectual property. 2019;3:28-31. Ukrainian.

Supplementary protection of inventions for the object of medicinal product. UNBA [Internet]. 2023 [cited 2023 May 14]. Available from: https://drive.google.com/file/d/16aIlMxcRm7LdAQAAJRcLGm5GiPTv90-C/view?fbclid=IwAR1E4dSyKs9xMshyzhWhV8y_hmMJs6hHYF1YuRgjRFObFY3_0ZiAznXjesI

Prokhoda Yu. [Problems of SPC. Supplementary protection of inventions for the object of medicinal product. Round Table]. Kyiv; 2023. 12 p. Ukrainian. Available from: https://drive.google.com/drive/folders/1DVux7EoLNhK-mEnVF4H4-2EbVI-PJOhl?fbclid=IwAR2zh7iUBhICA9s_PsEjil-ATR2u-a4_RjAu_99Zywt74Atqiwp3e9UT_Qw

Kislyi T. [The beginning of the application of the SPC regime: controversial issues. Supplementary protection of inventions for the object of medicinal product. Round Table]. Kyiv; 2023. 12 p. Ukrainian. Available from: https://drive.google.com/drive/folders/1DVux7EoLNhK-mEnVF4H4-2EbVI-PJOhl?fbclid=IwAR2zh7iUBhICA9s_PsEjil-ATR2u-a4_RjAu_99Zywt74Atqiwp3e9UT_Qw

[On approval of the Rules for drawing up, submitting and conducting examination of an application for an invention and an application for a utility model. Notice of publication of the draft order of the Ministry of Economy of Ukraine. Ministry of Economy of Ukraine]. [Internet]. 2022 Feb 18 [cited 2023 May 14]. Available from: https://me.gov.ua/Do¬cuments/Detail?lang=uk-UA&isSpecial=True&id=¬11b0bc41-5349-49a6-8453-9eb51d594ca2&title=Povi-domlenniaProOpriliudnenniaProktuNakazuMinisterstvaEkonomikiUkrainiproZatverdzhenniaPravilSkladannia-PodanniaTaProvedenniaEkspertiziZaiavkiNaVinakhidIZaiavkiNaKorisnuModel

Published

2023-09-29

How to Cite

1.
Kodynets A, Doroshenko O, Volynets I, Dorozhko G, Petrenko V, Belitsky V. Supplementary protection of intellectual property rights for medicines. Med. perspekt. [Internet]. 2023Sep.29 [cited 2024Mar.3];28(3):180-9. Available from: https://journals.uran.ua/index.php/2307-0404/article/view/289223

Issue

Section

SOCIAL MEDICINE